Moleculin Biotech (MBRX) Gets a Buy Rating from Maxim Group


In a report issued on March 26, Jason McCarthy from Maxim Group maintained a Buy rating on Moleculin Biotech (MBRX), with a price target of $18.00. The company’s shares closed last Monday at $4.91.

According to TipRanks.com, McCarthy is a top 25 analyst with an average return of 78.0% and a 73.5% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Appili Therapeutics Inc Class A, Brainstorm Cell Therapeutics, and SELLAS Life Sciences Group.

Currently, the analyst consensus on Moleculin Biotech is a Strong Buy with an average price target of $22.00, which is a 353.6% upside from current levels. In a report issued on March 20, Oppenheimer also maintained a Buy rating on the stock with a $12.00 price target.

See today’s analyst top recommended stocks >>

Moleculin Biotech’s market cap is currently $58.92M and has a P/E ratio of -2.40. The company has a Price to Book ratio of 3.98.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company, which focuses on the development of oncology drug candidates. Its Annamycin product candidate helps in the treatment of relapsed or refractory acute myeloid leukemia. The company’s preclinical small molecule portfolios focus on the modulation of hard-to-target tumor cell signaling mechanisms and the metabolism of tumors. Moleculin Biotech was founded by Walter V. Klemp, Donald H. Picker and Waldemar Priebe on July 28, 2015 and is headquartered in Houston, TX.

Read More on MBRX:

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts